Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02838797 · ClinicalTrials.gov registry record · Phase 1
RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT02838797 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 51 participants.
The verdict
NCT02838797, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
This is a study to determine the safety and tolerability of a new medicine (RQ10) for gastrointestinal symptoms in Parkinson's disease. The investigators will also begin to look at the effect of this medicine on gastrointestinal problems. The results will determine if future studies are appropriate. In this study, RQ10 will be compared to a placebo (a look-alike inactive substance). Participation will include multiple office visits. Approximately 48 people will participate.
Interventions
- DRUG Placebo
- DRUG RQ-00000010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2016-06 |
| Est. Completion | 2019-08-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02838797
The ClinicalTrials.gov registry entry for NCT02838797 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02838797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02838797 about?
NCT02838797 is a clinical study titled "RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease". This is a study to determine the safety and tolerability of a new medicine (RQ10) for gastrointestinal symptoms in Parkinson's disease. The investigators will also begin to look at the effect of this medicine on gastrointestinal problems. The results will determine if future studies are appropriate....
What is the current status of trial NCT02838797?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2016-06. Estimated completion is 2019-08-20.
What interventions are being tested in trial NCT02838797?
The interventions under investigation include: Placebo (DRUG), RQ-00000010 (DRUG).
Who is sponsoring clinical trial NCT02838797?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.